Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2014
  • Online publication date: August 2014

Chapter 11 - Preconception counseling for women with epilepsy

References

1. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ (Clinical research ed) 2000; 321(7262):674–5.
2. Bell GS, Nashef L, Kendall S, et al. Information recalled by women taking anti-epileptic drugs for epilepsy: a questionnaire study. Epilepsy Res 2002; 52(2):139–46.
3. May TW, Pfafflin M, Coban I, et al. Fears, knowledge, and need of counseling for women with epilepsy. Results of an outpatient study. Der Nervenarzt 2009; 80(2):174–83.
4. Vazquez B, Gibson P and Kustra R. Epilepsy and women’s health issues: unmet needs–survey results from women with epilepsy. Epilepsy Behav 2007; 10(1):163–9.
5. Winterbottom JB, Smyth RM, Jacoby A, et al. Preconception counselling for women with epilepsy to reduce adverse pregnancy outcome. Cochrane Database Syst Revi 2008; (3):CD006645.
6. Crawford P. Best practice guidelines for the management of women with epilepsy. Epilepsia 2005; 46(Suppl 9):117–24.
7. Aguglia U, Barboni G, Battino D, et al. Italian consensus conference on epilepsy and pregnancy, labor and puerperium. Epilepsia 2009; 50(Suppl 1):7–23.
8. Davis AR, Pack AM, Kritzer J, et al. Reproductive history, sexual behavior and use of contraception in women with epilepsy. Contraception 2008; 77(6):405–9.
9. Crawford P and Hudson S. Understanding the information needs of women with epilepsy at different lifestages: results of the “Ideal World” survey. Seizure 2003; 12(7):502–7.
10. Helbig KL, Bernhardt BA, Conway LJ, et al. Genetic risk perception and reproductive decision making among people with epilepsy. Epilepsia 2010; 51(9):1874–7.
11. Winawer MR and Shinnar S. Genetic epidemiology of epilepsy or what do we tell families? Epilepsia 2005; 46(Suppl 10):24–30.
12. Ottman R, Hirose S, Jain S, et al. Genetic testing in the epilepsies–report of the ILAE Genetics Commission. Epilepsia 2010; 51(4):655–70.
13. Kullman D. Genetics of Epilepsy. J Neurol Neurosurg Psychiatry 2002; 73(Suppl 2):ii32–ii5.
14. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. New Engl J Med 2001; 344(15):1132–8.
15. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77(2):193–8.
16. Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology. 2005; 64(11):1874–8.
17. Hernandez-Diaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012; 78(21):1692–9.
18. Tomson T, Battino D, Bonizzoni E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10(7):609–17.
19. Vajda FJ, Graham J, Roten A, et al. Teratogenicity of the newer antiepileptic drugs–the Australian experience. J Clin Neurosci 2012; 19(1):57–9.
20. Wide K, Winbladh B and Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93(2):174–6.
21. Molgaard-Nielsen D and Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011; 305(19):1996–2002.
22. Cunnington MC, Weil JG, Messenheimer JA, et al. Final results from 18 years of the International Lamotrigine Pregnancy Registry. Neurology 2011; 76(21):1817–23.
23. Tomson T and Battino D. Teratogenic effects of antiepileptic drugs. Lancet Neurol 2012; 11(9):803–13.
24. FDA Drug Safety Communication: risk of oral clefts in children born to mothers taking Topamax (topiramate). 2011. www.fda.gov/Drugs/DrugSafety/ucm245085.htm.
25. Vajda FJ, Hitchcock A, Graham J, et al. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007; 47(6):468–74.
26. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73(2):133–41.
27. Shallcross R, Bromley RL, Irwin B, et al. Child development following in utero exposure: levetiracetam vs sodium valproate. Neurology. 2011; 76(4):383–9. PubMed PMID: 21263139.
28. Banach R, Boskovic R, Einarson T, et al. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies. Drug Saf 2010; 33(1):73–9.
29. Meador KJ, Baker GA, Browning N, et al. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 2012; 78(16):1207–14.
30. Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008; 81(1):1–13.
31. Holmes LB, Mittendorf R, Shen A, et al. Fetal effects of anticonvulsant polytherapies: different risks from different drug combinations. Arch Neurol 2011; 68(10):1275–81.
32. Blencowe H, Cousens S, Modell B, et al. Folic acid to reduce neonatal mortality from neural tube disorders. In J Epidemiol 2010; 39(Suppl 1):i110–i21.
33. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. Lancet 1991; 338(8760):131–7.
34. Kaaja E, Kaaja R and Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60(4):575–9.
35. Kjaer D, Horvath-Puho E, Christensen J, et al. Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case-control study. BJOG 2008; 115(1):98–103.
36. Pittschieler S, Brezinka C, Jahn B, et al. Spontaneous abortion and the prophylactic effect of folic acid supplementation in epileptic women undergoing antiepileptic therapy. J Neurol 2008; 255(12):1926–31.
37. Harden CL, Pennell PB, Koppel BS, et al. Practice parameter update: management issues for women with epilepsy – focus on pregnancy (an evidence-based review): vitamin K, folic acid, blood levels, and breastfeeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73(2):142–9.
38. Meador KJ, Baker GA, Browning N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011; 134(2):396–404.
39. Wilson RD, Davies G, Desilets V, et al. The use of folic acid for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can 2003; 25(11):959–73.
40. Harden CL, Hopp J, Ting TY, et al. Practice parameter update: management issues for women with epilepsy–focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009; 73(2):126–32.
41. Pennell PB, Peng L, Newport DJ, et al. Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency. Neurology 2008; 70(22 Pt 2):2130–6.
42. Sabers A and Petrenaite V. Seizure frequency in pregnant women treated with lamotrigine monotherapy. Epilepsia 2009; 50(9):2163–6.
43. Kaplan PW, Norwitz ER, Ben-Menachem E, et al. Obstetric risks for women with epilepsy during pregnancy. Epilepsy Behav 2007; 11(3):283–91.
44. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75(11):1575–83.
45. EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology 2006; 66(3):354–60.
46. Rauchenzauner M, Ehrensberger M, Prieschl M, et al. Generalized tonic-clonic seizures and antiepileptic drugs during pregnancy-a matter of importance for the baby? J Neurol 2013; 260(2):484–8.
47. Chen YH, Chiou HY, Lin HC, et al. Affect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol 2009; 66(8):979–84.
48. Klein A. The postpartum period in women with epilepsy. Neurol Clin 2012; 30(3):867–75.
49. Meador KJ, Baker GA, Browning N, et al. Effects of breastfeeding in children of women taking antiepileptic drugs. Neurology 2010; 75(22):1954–60.
50. Lossius MI, Hessen E, Mowinckel P, et al. Consequences of antiepileptic drug withdrawal: a randomized, double-blind study (Akershus Study). Epilepsia 2008; 49(3):455–63.
51. Hunt S. Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008; 71(4):272–6.
52. Mawhinney E. Craig J, Morrow J, et al. Levetiracetam in pregnancy: results from the UK and Ireland epilepsy and pregnancy registers. Neurology 2013; 80(4):400–5.